v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | TCTR20220406002 |
Full text link
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
|
First author
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
|
Contact
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
orasriw@hotmail.com |
Registration date
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
2022-04-06 |
Recruitment status
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Recruiting |
Study design
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
RCT |
Allocation
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Randomized |
Design
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Sequential assignment |
Masking
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Open label |
Center
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
multi-center |
Study aim
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Prevention |
Inclusion criteria
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Males or females 5 - <, 16 years of age (inclusive) Never received any COVID-19 vaccine Participant or guardian of participant understand(s) Thai language through speaking, reading and writing Participant or guardian of participant be able to communicate through electronic tools such as Google form or line. Capable of attending all study visits according to the study schedule. Capable of informed assent/consent and provision of written informed consent before any study procedures |
Exclusion criteria
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Have history of severe drug or vaccine allergy Yes (anaphylaxis)? Have ever detected COVID-19 infection? Have history of COVID-19 high risk contact? Did not receive any vaccine within 14 days before the enrollment? Have received blood transfusion, plasma, blood product, blood component, immunoglobulins, antiviral or antibodies within the last 90 days? Being pregnant? Have unstable disease or could not control the symptom? Have history of immunodeficiency or been using immunosuppressant or steroid drugs? Had any of these chronic respiratory tract disease, cardiovascular disease, chronic kidney disease, diabetes, delayed development, and severe neurological conditions? Have any unusual symptoms or medical history that considered unable to participate in the study? |
Number of arms
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
4 |
Funding
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Program Management Unit for Competitiveness (PMUC) |
Inclusion age min
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
5 |
Inclusion age max
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
16 |
Countries
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Thailand |
Type of patients
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Healthy volunteers |
Severity scale
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
N/A |
Total sample size
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
800 |
primary outcome
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Adverse events within 7 days after vaccination and upto 12 weeks after 2nd dose Proportion of adverse events |
Notes
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
|
Phase
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Phase 1/Phase 2 |
Arms
Last imported at : May 5, 2022, 11:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
[{"arm_notes": "full dose, previous CoronaVac", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "half dose, previous CoronaVac", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "full dose, previous BNT162b2 (full dose)", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "half dose, previous BNT162b2 (half dose)", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}] |